New drug targets Hard-to-Treat cancers with BRCA2 or PALB2 mutations
Disease control
Recruiting now
This study tests an experimental drug called CX-5461 in people with advanced solid tumors (like pancreatic, prostate, breast, or ovarian cancer) that have specific gene changes in BRCA2 or PALB2. The goal is to find a safe dose and see if the drug can shrink tumors or slow their …
Phase: PHASE1 • Sponsor: Senhwa Biosciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC